BIAF - bioAffinity Technologies, Inc.


2.61
-0.080   -3.065%

Share volume: 224,168
Last Updated: 04-21-2026
Business Services/Services – Research, Development, Testing Labs: -0.03%

PREVIOUS CLOSE
CHG
CHG%

$2.69
-0.08
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
36%
Profitability 35%
Dept financing 30%
Liquidity 68%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-8.74%
1 Month
-44.82%
3 Months
91.91%
6 Months
3.57%
1 Year
411.76%
2 Year
-13.00%
Key data
Stock price
$2.61
P/E Ratio 
N/A
DAY RANGE
$2.61 - $2.83
EPS 
-$6.88
52 WEEK RANGE
$0.13 - $7.29
52 WEEK CHANGE
$427.59
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
4.499 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.39
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$341,845
AVERAGE 30 VOLUME 
$5,261,768
Company detail
CEO: Maria Zannes
Region: US
Website: bioaffinitytech.com
Employees: 10
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

bioAffinity Technologies, Inc. is a privately held company incorporated in Delaware addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Our principal executive office is located at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257, and our telephone number at that address is (210) 698-5334. Our laboratory diagnostic and therapeutic research is conducted at The Harvey Sandler Cancer Research Laboratories, which is located at Science Research Laboratories, Suite 1.424, University of Texas at San Antonio, San Antonio, Texas.

Recent news